文献速递白血病

识别多变量微小RNA与临床生物标志物组合以预测初诊慢性髓性白血病患者的伊马替尼反应

Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis.
PubMed 文献 · Leukemia · 2023-10-17

研究分析80例初诊慢性髓性白血病患者CD34+细胞中差异表达的微小RNA及临床数据,患者后续被分类为伊马替尼应答者或无应答者。Cox比例风险分析识别出16个与伊马替尼无应答相关的微小RNA。机器学习模型显示微小RNA联合临床特征的多变量组合预测性能优于单一微小RNA或临床特征组合。

要点

  • Cox比例风险分析识别出16个与伊马替尼无应答相关的微小RNA。
  • 微小RNA联合临床特征的多变量组合预测性能优于单一微小RNA或临床特征组合。
  • 研究结果可能为未来预测性生物标志物研究提供信息。

核心结论

  • 由微小RNA和临床特征组成的多变量组合预测伊马替尼反应的表现优于单一微小RNA或临床特征组合。
  • 研究结果可能为未来预测性生物标志物研究提供信息,并作为工具为临床慢性髓性白血病患者制定更优化的治疗方案。

研究设计与样本

  • 研究分析80例初诊慢性髓性白血病患者CD34+细胞中的临床数据和差异表达微小RNA,患者后续被分类为伊马替尼应答者或无应答者。
  • 采用Cox比例风险分析识别与伊马替尼无应答相关的微小RNA。
  • 训练机器学习模型,使用16个微小RNA的不同组合并联合或不联合临床参数。

主要发现

  • Cox比例风险分析识别出16个与伊马替尼无应答相关且在这些患者中差异表达的微小RNA。
  • 基于受试者工作特征曲线和精确率-召回率曲线下面积值,识别出具有高预测性能的组合。
  • 由微小RNA和临床特征组成的多变量组合预测性能优于单一微小RNA组合或临床特征组合。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Imatinib Mesylate (imatinib) was once hailed as the magic bullet for chronic myeloid leukemia (CML) and remains a front-line therapy for CML to this day alongside other tyrosine kinase inhibitors (TKIs). However, TKI treatments are rarely curative and patients are often required to receive life-long treatment or otherwise risk relapse. Thus, there is a growing interest in identifying biomarkers in patients which can predict TKI response upon diagnosis. In this study, we analyze clinical data and differentially expressed miRNAs in CD34+ CML cells from 80 patients at diagnosis who were later classified as imatinib-responders or imatinib-nonresponders. A Cox Proportional Hazard (CoxPH) analysis identified 16 miRNAs that were associated with imatinib nonresponse and differentially expressed in these patients. We also trained a machine learning model with different combinations of the 16 miRNAs with and without clinical parameters and identified a panel with high predictive performance based on area-under-curve values of receiver-operating-characteristic and precision-recall curves. Interestingly, the multivariable panel consisting of both miRNAs and clinical features performed better than either miRNA or clinical panels alone. Thus, our findings may inform future studies on predictive biomarkers and serve as a tool to develop more optimized treatment plans for CML patients in the clinic.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Wu A, Yen R, Grasedieck S, et al. Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis. Leukemia. 2023. PMID: 37848633. doi:10.1038/s41375-023-02062-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。